432 related articles for article (PubMed ID: 26158270)
1. Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent.
Reh L; Magnus C; Schanz M; Weber J; Uhr T; Rusert P; Trkola A
PLoS Pathog; 2015 Jul; 11(7):e1004966. PubMed ID: 26158270
[TBL] [Abstract][Full Text] [Related]
2. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
Li H; Zony C; Chen P; Chen BK
J Virol; 2017 May; 91(9):. PubMed ID: 28148796
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.
Stefic K; Bouvin-Pley M; Essat A; Visdeloup C; Moreau A; Goujard C; Chaix ML; Braibant M; Meyer L; Barin F
J Virol; 2019 Jan; 93(2):. PubMed ID: 30404804
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.
Ditse Z; Muenchhoff M; Adland E; Jooste P; Goulder P; Moore PL; Morris L
J Virol; 2018 Sep; 92(17):. PubMed ID: 29950423
[TBL] [Abstract][Full Text] [Related]
5. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
[TBL] [Abstract][Full Text] [Related]
6. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.
Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431
[TBL] [Abstract][Full Text] [Related]
7. Single-Chain Variable Fragments of Broadly Neutralizing Antibodies Prevent HIV Cell-Cell Transmission.
van Dorsten RT; Reh L; Trkola A; Morris L; Moore PL
J Virol; 2022 Feb; 96(4):e0193421. PubMed ID: 34935437
[TBL] [Abstract][Full Text] [Related]
8. Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV.
Zhang Y; Chapman JH; Ulcay A; Sutton RE
J Virol; 2019 Feb; 93(4):. PubMed ID: 30518644
[TBL] [Abstract][Full Text] [Related]
9. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
[TBL] [Abstract][Full Text] [Related]
10. Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope.
Anthony C; York T; Bekker V; Matten D; Selhorst P; Ferreria RC; Garrett NJ; Karim SSA; Morris L; Wood NT; Moore PL; Williamson C
J Virol; 2017 Sep; 91(18):. PubMed ID: 28679760
[TBL] [Abstract][Full Text] [Related]
11. Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection.
Wagh K; Bhattacharya T; Williamson C; Robles A; Bayne M; Garrity J; Rist M; Rademeyer C; Yoon H; Lapedes A; Gao H; Greene K; Louder MK; Kong R; Karim SA; Burton DR; Barouch DH; Nussenzweig MC; Mascola JR; Morris L; Montefiori DC; Korber B; Seaman MS
PLoS Pathog; 2016 Mar; 12(3):e1005520. PubMed ID: 27028935
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs.
Ren Y; Korom M; Truong R; Chan D; Huang SH; Kovacs CC; Benko E; Safrit JT; Lee J; Garbán H; Apps R; Goldstein H; Lynch RM; Jones RB
J Virol; 2018 Dec; 92(23):. PubMed ID: 30209173
[TBL] [Abstract][Full Text] [Related]
13. Viral Characteristics Associated with Maintenance of Elite Neutralizing Activity in Chronically HIV-1 Clade C-Infected Monozygotic Pediatric Twins.
Mishra N; Makhdoomi MA; Sharma S; Kumar S; Dobhal A; Kumar D; Chawla H; Singh R; Kanga U; Das BK; Lodha R; Kabra SK; Luthra K
J Virol; 2019 Sep; 93(17):. PubMed ID: 31217240
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
[TBL] [Abstract][Full Text] [Related]
15. Neutralisation of HIV-1 cell-cell spread by human and llama antibodies.
McCoy LE; Groppelli E; Blanchetot C; de Haard H; Verrips T; Rutten L; Weiss RA; Jolly C
Retrovirology; 2014 Oct; 11():83. PubMed ID: 25700025
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission.
Gombos RB; Kolodkin-Gal D; Eslamizar L; Owuor JO; Mazzola E; Gonzalez AM; Korioth-Schmitz B; Gelman RS; Montefiori DC; Haynes BF; Schmitz JE
J Virol; 2015 Aug; 89(15):7813-28. PubMed ID: 25995259
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 Coreceptor Usage and Variable Loop Contact Impact V3 Loop Broadly Neutralizing Antibody Susceptibility.
Registre L; Moreau Y; Ataca ST; Pulukuri S; Henrich TJ; Lin N; Sagar M
J Virol; 2020 Jan; 94(2):. PubMed ID: 31694950
[TBL] [Abstract][Full Text] [Related]
18. Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1.
Sather DN; Carbonetti S; Malherbe DC; Pissani F; Stuart AB; Hessell AJ; Gray MD; Mikell I; Kalams SA; Haigwood NL; Stamatatos L
J Virol; 2014 Nov; 88(22):12968-81. PubMed ID: 25122781
[TBL] [Abstract][Full Text] [Related]
19. Systematic Assessment of Antiviral Potency, Breadth, and Synergy of Triple Broadly Neutralizing Antibody Combinations against Simian-Human Immunodeficiency Viruses.
Berendam SJ; Styles TM; Morgan-Asiedu PK; Tenney D; Kumar A; Obregon-Perko V; Bar KJ; Saunders KO; Santra S; De Paris K; Tomaras GD; Chahroudi A; Permar SR; Amara RR; Fouda GG
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177194
[TBL] [Abstract][Full Text] [Related]
20. Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.
Freund NT; Wang H; Scharf L; Nogueira L; Horwitz JA; Bar-On Y; Golijanin J; Sievers SA; Sok D; Cai H; Cesar Lorenzi JC; Halper-Stromberg A; Toth I; Piechocka-Trocha A; Gristick HB; van Gils MJ; Sanders RW; Wang LX; Seaman MS; Burton DR; Gazumyan A; Walker BD; West AP; Bjorkman PJ; Nussenzweig MC
Sci Transl Med; 2017 Jan; 9(373):. PubMed ID: 28100831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
